187 related articles for article (PubMed ID: 33307191)
1. Prospective Observational Study Revealing Early Pulmonary Function Changes Associated With Brigatinib Initiation.
Ng TL; Johnson A; Nemenoff RA; Hsieh E; Osypuk AA; van Bokhoven A; Li H; Camidge DR; Schenk EL
J Thorac Oncol; 2021 Mar; 16(3):486-491. PubMed ID: 33307191
[TBL] [Abstract][Full Text] [Related]
2. Management Strategies for Early-Onset Pulmonary Events Associated with Brigatinib.
Camidge DR; Pabani A; Miller RM; Rizvi NA; Bazhenova L
J Thorac Oncol; 2019 Sep; 14(9):1547-1555. PubMed ID: 31108247
[TBL] [Abstract][Full Text] [Related]
3. Early-Onset Pulmonary Events Associated With Brigatinib Use in Advanced NSCLC.
Ng TL; Narasimhan N; Gupta N; Venkatakrishnan K; Kerstein D; Camidge DR
J Thorac Oncol; 2020 Jul; 15(7):1190-1199. PubMed ID: 32135189
[TBL] [Abstract][Full Text] [Related]
4. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR
Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716
[TBL] [Abstract][Full Text] [Related]
5. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
Camidge DR; Kim HR; Ahn MJ; Yang JCH; Han JY; Hochmair MJ; Lee KH; Delmonte A; García Campelo MR; Kim DW; Griesinger F; Felip E; Califano R; Spira A; Gettinger SN; Tiseo M; Lin HM; Gupta N; Hanley MJ; Ni Q; Zhang P; Popat S
J Clin Oncol; 2020 Nov; 38(31):3592-3603. PubMed ID: 32780660
[TBL] [Abstract][Full Text] [Related]
6. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
Kim DW; Tiseo M; Ahn MJ; Reckamp KL; Hansen KH; Kim SW; Huber RM; West HL; Groen HJM; Hochmair MJ; Leighl NB; Gettinger SN; Langer CJ; Paz-Ares Rodríguez LG; Smit EF; Kim ES; Reichmann W; Haluska FG; Kerstein D; Camidge DR
J Clin Oncol; 2017 Aug; 35(22):2490-2498. PubMed ID: 28475456
[TBL] [Abstract][Full Text] [Related]
7. Prospective Long-Term Follow-Up of Pulmonary Diffusion Capacity Reduction Caused by Dose-Dense Chemotherapy in Patients with Breast Cancer.
Landman Y; Stemmer SM; Sulkes A; Neiman V; Granot T; Hendler D; Kramer MR; Gelmon K; Yerushalmi R
J Oncol; 2019; 2019():2584859. PubMed ID: 31772578
[TBL] [Abstract][Full Text] [Related]
8. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
Camidge DR; Kim HR; Ahn MJ; Yang JC; Han JY; Lee JS; Hochmair MJ; Li JY; Chang GC; Lee KH; Gridelli C; Delmonte A; Garcia Campelo R; Kim DW; Bearz A; Griesinger F; Morabito A; Felip E; Califano R; Ghosh S; Spira A; Gettinger SN; Tiseo M; Gupta N; Haney J; Kerstein D; Popat S
N Engl J Med; 2018 Nov; 379(21):2027-2039. PubMed ID: 30280657
[TBL] [Abstract][Full Text] [Related]
9. Performance capacity evaluated using the 6-minute walk test: 5-year results in patients with diffuse systemic sclerosis and initial interstitial lung disease.
Rizzi M; Sarzi-Puttini P; Airoldi A; Antivalle M; Battellino M; Atzeni F
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S142-7. PubMed ID: 26339893
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with dyspnea in adult patients with sickle cell disease.
Delclaux C; Zerah-Lancner F; Bachir D; Habibi A; Monin JL; Godeau B; Galacteros F
Chest; 2005 Nov; 128(5):3336-44. PubMed ID: 16304281
[TBL] [Abstract][Full Text] [Related]
11. Serial lung function testing in patients treated with amiodarone: a prospective study.
Gleadhill IC; Wise RA; Schonfeld SA; Scott PP; Guarnieri T; Levine JH; Griffith LS; Veltri EP
Am J Med; 1989 Jan; 86(1):4-10. PubMed ID: 2910095
[TBL] [Abstract][Full Text] [Related]
12. Different diffusing capacity of the lung for carbon monoxide as predictors of respiratory morbidity.
Cerfolio RJ; Bryant AS
Ann Thorac Surg; 2009 Aug; 88(2):405-10; discussion 410-1. PubMed ID: 19632384
[TBL] [Abstract][Full Text] [Related]
13. Early exercise pulmonary diffusing capacity of carbon monoxide after anatomical lung resection: a word of caution for fast-track programmes.
Novoa NM; Esteban P; Gómez Hernández MT; Fuentes MG; Varela G; Jiménez MF
Eur J Cardiothorac Surg; 2019 Jul; 56(1):143-149. PubMed ID: 30726898
[TBL] [Abstract][Full Text] [Related]
14. Impaired diffusion capacity predicts for decreased treatment tolerance and survival in limited stage small cell lung cancer patients treated with concurrent chemoradiation.
Videtic GM; Stitt LW; Ash RB; Truong PT; Dar AR; Yu EW; Whiston F
Lung Cancer; 2004 Feb; 43(2):159-66. PubMed ID: 14739036
[TBL] [Abstract][Full Text] [Related]
15. The effect of pulmonary function testing on bleomycin dosing in germ cell tumours.
Roncolato FT; Chatfield M; Houghton B; Toner G; Stockler M; Thomson D; Friedlander M; Gurney H; Rosenthal M; Grimison P;
Intern Med J; 2016 Aug; 46(8):893-8. PubMed ID: 27305276
[TBL] [Abstract][Full Text] [Related]
16. A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin.
Dimopoulou I; Galani H; Dafni U; Samakovii A; Roussos C; Dimopoulos MA
Cancer; 2002 Jan; 94(2):452-8. PubMed ID: 11900231
[TBL] [Abstract][Full Text] [Related]
17. Respiratory function changes after chemotherapy: an additional risk for postoperative respiratory complications?
Leo F; Solli P; Spaggiari L; Veronesi G; de Braud F; Leon ME; Pastorino U
Ann Thorac Surg; 2004 Jan; 77(1):260-5; discussion 265. PubMed ID: 14726074
[TBL] [Abstract][Full Text] [Related]
18. Isolated DLco/VA reduction in systemic sclerosis patients: a new patient subset?
Corzo P; Pros A; Martinez-Llorens J; Molina L; Ling SF; Balcells E
Clin Rheumatol; 2018 Dec; 37(12):3365-3371. PubMed ID: 30368639
[TBL] [Abstract][Full Text] [Related]
19. COPD patients with severe diffusion defect in carbon monoxide diffusing capacity predict a better outcome for pulmonary rehabilitation.
Sahin H; Naz I; Varol Y; Aksel N; Tuksavul F; Ozsoz A
Rev Port Pneumol (2006); 2016; 22(6):323-330. PubMed ID: 27134123
[TBL] [Abstract][Full Text] [Related]
20. Change in diffusing capacity after radiation as an objective measure for grading radiation pneumonitis in patients treated for non-small-cell lung cancer.
Lopez Guerra JL; Gomez D; Zhuang Y; Levy LB; Eapen G; Liu H; Mohan R; Komaki R; Cox JD; Liao Z
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1573-9. PubMed ID: 22768989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
